Back to Newsroom

Cempra Milestone Highlights Experimental Antibiotic’s Potential

Cempra Pharmaceuticals’ (NASDAQ: CEMP) efforts to bring patients a next-generation antibiotic that could help address drug-resistant bacteria now has a boost from Japan.

The Chapel Hill, NC, company last year licensed Japanese development and commercialization rights for its solithromycin to Toyama Chemical Co. in a deal that could pay up to $60 million in milestones. Cempra now says Toyama completed Phase 1 trials of the antibiotic and received the regulatory go ahead to start Phase 2 trials, a milestone that triggers a $10 million payment to Cempra.

Click here to read more